Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non‑small cell lung cancer

  • Authors:
    • Sushant Kumar Das
    • Ya‑Yong Huang
    • Bing Li
    • Xiao Xuan Yu
    • Ru Hui Xiao
    • Han Feng Yang
  • View Affiliations

  • Published online on: November 25, 2019     https://doi.org/10.3892/ol.2019.11149
  • Pages: 1031-1041
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to compare the safety and efficacy of cryoablation (CA) and microwave ablation (MWA) as treatments for non‑small cell lung cancer (NSCLC). Patients with stage IIIB or IV NSCLC treated with CA (n=45) or MWA (n=56) were enrolled in the present study. The primary endpoint was progression‑free survival (PFS); the secondary endpoints included overall survival (OS) time and adverse events (AEs). The median PFS times between the two groups were not significantly different (P=0.36): CA, 10 months [95% confidence interval (CI), 7.5‑12.4] vs. MWA, 11 months (95% CI, 9.5‑12.4). The OS times between the two groups were also not significantly different (P=0.07): CA, 27.5 months (95% CI, 22.8‑31.2 months) vs. MWA, 18 months (95% CI, 12.5‑23.5). For larger tumors (>3 cm), patients treated with MWA had significantly longer median PFS (P=0.04; MWA, 10.5 months vs. CA, 7.0 months) and OS times (P=0.04; MWA, 24.5 months vs. CA, 14.5 months) compared patients treated with CA. However, for smaller tumors (≤3 cm), median PFS (P=0.79; MWA, 11.0 months vs. CA, 13.0 months) and OS times (P=0.39; MWA, 30.0 months vs. CA, 26.5 months) between the two groups did not differ significantly. The incidence rates of AEs were similar in the two groups (P>0.05). The number of applicators, tumor size and length of the lung traversed by applicators were associated with a higher risk of pneumothorax and intra‑pulmonary hemorrhage in the two groups. Treatment with CA resulted in significantly less intraprocedural pain compared with treatment with MWA (P=0.001). Overall, the present study demonstrated that CA and MWA were comparably safe and effective procedures for the treatment of small tumors. However, treatment with MWA was superior compared with CA for the treatment of large tumors.
View Figures
View References

Related Articles

Journal Cover

January-2020
Volume 19 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Das SK, Huang YY, Li B, Yu XX, Xiao RH and Yang HF: Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non‑small cell lung cancer . Oncol Lett 19: 1031-1041, 2020.
APA
Das, S.K., Huang, Y., Li, B., Yu, X.X., Xiao, R.H., & Yang, H.F. (2020). Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non‑small cell lung cancer . Oncology Letters, 19, 1031-1041. https://doi.org/10.3892/ol.2019.11149
MLA
Das, S. K., Huang, Y., Li, B., Yu, X. X., Xiao, R. H., Yang, H. F."Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non‑small cell lung cancer ". Oncology Letters 19.1 (2020): 1031-1041.
Chicago
Das, S. K., Huang, Y., Li, B., Yu, X. X., Xiao, R. H., Yang, H. F."Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non‑small cell lung cancer ". Oncology Letters 19, no. 1 (2020): 1031-1041. https://doi.org/10.3892/ol.2019.11149